Indica Labs, a provider of computational pathology software and services, has announced a CE-IVD mark for HALO Prostate AI, a screening tool designed to assist pathologists in identifying and grading prostate cancer in needle biopsies.
Prostate cancer is the most common cancer diagnosed in men. With over 1.4 million cases reported worldwide in 2020, the incidence rates continue to rise with wider availability of screening tests, such as PSA. Each prostate case consists of multiple biopsy core whole slide images, which must be assessed by a pathologist for the presence of tumour and, if present, a Gleason score is reported. This represents a large workload for pathologists who screen multiple cases daily. HALO Prostate AI is designed to work alongside the pathologist to improve efficiency and to add a layer of quality control to ensure diagnostic accuracy.
Developed in close collaboration with Dr Yuri Tolkach and colleagues from the University of Cologne, HALO Prostate AI was trained using over 870,000 training patches obtained from the annotation of digital scans representing the full spectrum of prostate cancer subtypes and Gleason grades, as well as benign tissue. The algorithm achieved high sensitivity (95–100%), specificity (88–98%) and negative predictive value (98–100%) in validation studies performed on 4973 core needle biopsies from three independent cohorts sourced from hospitals in Austria and Germany. Highlighting the unique benefit of HALO Prostate AI screening on diagnostic accuracy and patient care, the algorithm correctly detected tumour in 26 cores within the validation study that were originally reported as tumour negative.
In a separate study, Gleason scores obtained from HALO Prostate AI were compared against scores assigned by pathologists located in 10 globally distributed hospitals. Nine pathologists who participated in the study were board-certified in genitourinary pathology. High concordance was achieved for two separate cohorts with representative average quadratic Kappa scores of 0.8 and 0.7.
"I am very excited about the digital future of pathology," commented Dr Tolkach. "With tools such as HALO Prostate AI, our work can be substantially optimised while controlling for high-quality, reliable and objective diagnostics. HALO Prostate AI showed very high accuracy in the large multi-institutional study for tumour detection and Gleason grading in prostate biopsies. It’s really enjoyable to work back-to-back with such a powerful AI assistant."
Dr Peter Caie, Principal Scientist of AI Collaboration at Indica Labs, added, "This has been a hugely positive collaboration with Dr Tolkach and contributing pathologists from around the world. We set out to build a clinical-grade algorithm that could improve turnaround time and diagnostic accuracy for prostate cancer patients, and I believe that is exactly what we have achieved. We are thrilled to see the first of many AI algorithms from Indica Labs attain CE-IVD marking and to begin to be used in clinical settings to help alleviate the pressure of ever-increasing workloads."
